Currently out of the existing stock ratings of Ryan Zimmerman, 221 are a BUY (89.11%), 23 are a HOLD (9.27%), 4 are a SELL (1.61%).

Ryan Zimmerman

Work Performance Price Targets & Ratings Chart

Analyst Ryan Zimmerman, currently employed at BTIG, carries an average stock price target met ratio of 58.72% that have a potential upside of 30.71% achieved within 192 days.

Ryan Zimmerman’s has documented 463 price targets and ratings displayed on 29 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on RXST, Rxsight at 09-Jul-2025.

Wall Street Analyst Ryan Zimmerman

Analyst best performing recommendations are on ORGO (ORGANOGENESIS HOLDINGS).
The best stock recommendation documented was for STAA (STAAR SURGICAL COMPANY) at 12/28/2022. The price target of $67 was fulfilled within 14 days with a profit of $20.18 (43.1%) receiving and performance score of 30.79.

Average potential price target upside

of $40.67 (13.69%) on ISRG (INTUITIVE SURGICAL).
of $33.01 (17.73%) on PEN (PENUMBRA).
of $30.46 (13.17%) on SYK (STRYKER).

ALC Alcon AG GKOS Glaukos Corp GMED Globus Medical HUMA Humacyte IART Integra LifeSciences Holdings ISRG Intuitive Surgical KIDS Orthopediatrics Corp MDWD Mediwound Ltd MSON Misonix NUVA NuVasive ORGO Organogenesis Holdings PEN Penumbra RXST Rxsight SPNE SeaSpine Holdings Corp SRGA Surgalign Holdings SYK Stryker TCMD Tactile Systems Technology VCEL Vericel Corp Ord ZBH Zimmer Biomet Holdings HOLX Hologic MDT Medtronic PLC ABT Abbott Laboratories TMCI Treace Medical Concepts STAA STAAR Surgical Company RBOT Vicarious Surgical RCEL Avita Medical Ltd OFIX Orthofix Medical GEHC GE HealthCare Technologies MDAI Spectral AI

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Christoph Gretler (CREDIT SUISSE)